Business Context and Reporting Period
This Form 8-K is a current report filed by Bionano Genomics, Inc. on June 5, 2026, covering events occurring on June 2, 2026. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol BNGO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change reported is the departure of a senior executive:
- Departure of Chief Medical Officer: Alka Chaubey, Ph.D., resigned as Chief Medical Officer.
- Effective Date: The resignation is effective July 5, 2026.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The document is limited to the notification of the executive departure under Item 5.02.
Investor Verification Checklist
- Verify the timeline for the appointment of a new Chief Medical Officer to replace Dr. Chaubey.
- Confirm whether the resignation was voluntary or part of a broader strategic shift.
- Review subsequent filings for any impact on ongoing clinical trials or medical strategy.